Neutrophil-mediated IL-6 receptor trans-signaling and the risk of chronic obstructive pulmonary disease and asthma
Open Access
- 17 February 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 26 (8) , 1584-1596
Abstract
The Asp358Ala variant in the interleukin-6 receptor (IL-6R) gene has been implicated in asthma, autoimmune and cardiovascular disorders, but its role in other respiratory conditions such as chronic obstructive pulmonary disease (COPD) has not been investigated. The aims of this study were to evaluate whether there is an association between Asp358Ala and COPD or asthma risk, and to explore the role of the Asp358Ala variant in sIL-6R shedding from neutrophils and its pro-inflammatory effects in the lung. We undertook logistic regression using data from the UK Biobank and the ECLIPSE COPD cohort. Results were meta-analyzed with summary data from a further three COPD cohorts (7,519 total cases and 35,653 total controls), showing no association between Asp358Ala and COPD (OR = 1.02 [95% CI: 0.96, 1.07]). Data from the UK Biobank showed a positive association between the Asp358Ala variant and atopic asthma (OR = 1.07 [1.01, 1.13]). In a series of in vitro studies using blood samples from 37 participants, we found that shedding of sIL-6R from neutrophils was greater in carriers of the Asp358Ala minor allele than in non-carriers. Human pulmonary artery endothelial cells cultured with serum from homozygous carriers showed an increase in MCP-1 release in carriers of the minor allele, with the difference eliminated upon addition of tocilizumab. In conclusion, there is evidence that neutrophils may be an important source of sIL-6R in the lungs, and the Asp358Ala variant may have pro-inflammatory effects in lung cells. However, we were unable to identify evidence for an association between Asp358Ala and COPD.Keywords
Funding Information
- UK Medical Research Council (MR/L003120/1 and MR/J00345X/1)
- British Heart Foundation (RG/13/13/30194)
- UK Medical Research Council (G0800270)
- British Heart Foundation (SP/09/002)
- GlaxoSmithKline (SCO104960)
- National Institutes of Health (R01 HL089897 and R01 HL089856)
- GlaxoSmithKline (RES11080)
This publication has 52 references indexed in Scilit:
- Large-scale association analysis identifies new risk loci for coronary artery diseaseNature Genetics, 2012
- High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritisNature Genetics, 2012
- The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysisThe Lancet, 2012
- Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studiesThe Lancet, 2012
- Large-Scale Candidate Gene Analysis in Whites and African Americans Identifies IL6R Polymorphism in Relation to Atrial FibrillationCirculation: Cardiovascular Genetics, 2011
- Identification of IL6R and chromosome 11q13.5 as risk loci for asthmaThe Lancet, 2011
- Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage‐escalation studyArthritis & Rheumatism, 2010
- Associations of IL6 polymorphisms with lung function decline and COPDThorax, 2009
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002